<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 70 year-old man comes to the emergency department for sudden loss of vision in the right eye over the last 24 hours. He has noticed progressive bilateral loss of central vision over the last year. He has had difficulty reading his newspaper and watching his television. He has smoked 1 pack daily for 50 years. Ophthalmologic examination shows visual acuity of 2060 in the left eye and 20200 in the right eye. The pupils are equal and reactive to light. Tonometry reveals an intraocular pressure of 18 mm Hg in the right eye and 20 mm Hg in the left eye. Anterior segment exam is unremarkable. Slit-lamp examination shows subretinal fluid and small hemorrhage with grayish-green discoloration in the macular area in the right eye, and multiple drusen in the left eye with retinal pigment epithelial changes. Which of the following is the most appropriate initial treatment for the patients illness?? A: Etanercept, B: Thermal laser photocoagulation, C: Ranibizumab, D: Macular translocation surgery, E: Photodynamic therapy,  <response>: This is a question about the appropriate initial treatment for a 70 year old man with sudden vision loss in the right eye and progressive bilateral central vision loss over the past year. Key findings include a history of heavy smoking, visual acuity of 2060 in the left eye and 20200 in the right eye, normal pupils, normal intraocular pressures, subretinal fluid and hemorrhage in the right macula, and drusen with RPE changes in the left eye. This clinical presentation is most consistent with wet age-related macular degeneration AMD with a choroidal neovascular membrane CNVM in the right eye. The choices include medications like etanercept a TNF inhibitor and ranibizumab an anti-VEGF agent, as well as procedures like laser photocoagulation, macular translocation surgery, and photodynamic therapy. For wet AMD with a new CNVM, anti-VEGF therapy is the most appropriate initial treatment.C: Ranibizumab 